Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

4D-710

Gene therapy (AAV vector) · Gene replacement

Phase 2 Most advanced trial
1 Registered trials

What is 4D-710?

4D-710 is an adeno-associated virus (AAV) gene therapy with a capsid variant, 4D-A101, carrying a transgene for human CFTR with a deletion in its regulatory domain (CFTRΔR). It is studied in cystic fibrosis of the lung.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Respiratory
In trials of
FDMT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
9SG6QLJ7VJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05248230 Phase 2 Cystic Fibrosis Lung Recruiting FDMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis Lung

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.